Table 1.

Clinical characteristics of the study subjects who completed the intervention

Polyphenon E (n = 24)Placebo (n = 24)Pa
Age, y, n (%)
 Mean ± SD63.4 ± 5.961.3 ± 5.70.25
 <6512 (50)18 (75)0.14
 ≥6512 (50)6 (25)
Race, n (%)
 White23 (96)22 (92)1.00
 Native American01 (4)
 Other (multiracial)1 (4)1 (4)
Body mass index, kg/m2, n (%)
 Mean ± SD26.9 ± 3.428.1 ± 3.80.25
 <257 (29)6 (25)1.00
 25–29.912 (50)12 (50)
 ≥305 (21)6 (25)
PSA at diagnosis, ng/mL, n (%)
 Mean ± SD6.71 ± 4.047.90 ± 5.540.38
 <43 (12.5)3 (12.5)0.71
 4–1018 (75.0)16 (66.7)
 11–203 (12.5)3 (12.5)
 >200 (0.0)2 (8.3)
Biopsy Gleason score, n (%)
 6 (3 + 3)17 (70.8)17 (70.8)1.00
 7 (3 + 4)3 (12.5)3 (12.5)
 7 (4 + 3)1 (4.2)2 (8.3)
 ≥83 (12.5)2 (8.3)
  • aDerived from an unequal variance 2-sample t test for continuous outcome and from a Fisher exact test for categorical outcome.